PE20081264A1 - Anticuerpos agonistas anti-notch3 - Google Patents

Anticuerpos agonistas anti-notch3

Info

Publication number
PE20081264A1
PE20081264A1 PE2007001412A PE2007001412A PE20081264A1 PE 20081264 A1 PE20081264 A1 PE 20081264A1 PE 2007001412 A PE2007001412 A PE 2007001412A PE 2007001412 A PE2007001412 A PE 2007001412A PE 20081264 A1 PE20081264 A1 PE 20081264A1
Authority
PE
Peru
Prior art keywords
gene
family
heavy chain
constant region
sequence
Prior art date
Application number
PE2007001412A
Other languages
English (en)
Spanish (es)
Inventor
Kang Li
Bin-Bing Stephen Zhou
Wenjuan Wu
Sek Chung Fung
Sanjaya Singh
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20081264A1 publication Critical patent/PE20081264A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
PE2007001412A 2006-10-19 2007-10-18 Anticuerpos agonistas anti-notch3 PE20081264A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85286106P 2006-10-19 2006-10-19
US87921807P 2007-01-06 2007-01-06

Publications (1)

Publication Number Publication Date
PE20081264A1 true PE20081264A1 (es) 2008-10-01

Family

ID=39325263

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001412A PE20081264A1 (es) 2006-10-19 2007-10-18 Anticuerpos agonistas anti-notch3

Country Status (19)

Country Link
US (5) US7915390B2 (cg-RX-API-DMAC7.html)
EP (1) EP2087006B1 (cg-RX-API-DMAC7.html)
JP (1) JP5478254B2 (cg-RX-API-DMAC7.html)
KR (2) KR101525629B1 (cg-RX-API-DMAC7.html)
AR (1) AR063494A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007309229B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0715989A8 (cg-RX-API-DMAC7.html)
CA (1) CA2666672A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002987A1 (cg-RX-API-DMAC7.html)
CO (1) CO6180445A2 (cg-RX-API-DMAC7.html)
CR (1) CR10730A (cg-RX-API-DMAC7.html)
MA (1) MA30900B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009004106A (cg-RX-API-DMAC7.html)
NO (1) NO20091926L (cg-RX-API-DMAC7.html)
PE (1) PE20081264A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500576A1 (cg-RX-API-DMAC7.html)
RU (1) RU2461569C2 (cg-RX-API-DMAC7.html)
TW (1) TW200824707A (cg-RX-API-DMAC7.html)
WO (1) WO2008051797A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2008057144A2 (en) * 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
CL2007002989A1 (es) * 2006-10-19 2008-05-16 Genentech Inc Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3.
CA2666672A1 (en) 2006-10-19 2008-05-02 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
JP5618544B2 (ja) * 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US9127085B2 (en) * 2007-08-23 2015-09-08 The Trustees Of Columbia University In The City Of New York Compositions of humanized notch fusion proteins and methods of treatment
MX2011000233A (es) * 2008-07-08 2011-05-19 Oncomed Pharm Inc Agentes de union del receptor notch1 y metodos para su uso.
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
SG193873A1 (en) * 2008-08-22 2013-10-30 Univ Columbia Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
US8404239B2 (en) * 2008-10-01 2013-03-26 Genentech, Inc. Anti-Notch2 NRR antibodies
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
JP5113812B2 (ja) * 2009-08-31 2013-01-09 清 中川 コロニーピッキング装置、コロニーピッキング方法、及び融合細胞クローン作製方法
EP2483311B1 (en) 2009-09-30 2016-05-18 F.Hoffmann-La Roche Ag Anti-Notch3 antagonistic antibodies for treating of a gamma-secretase inhibitor positive T-cell leukemia that does not respond to an anti-Notch1 antagonistic antibody.
CN102958534B (zh) 2010-01-13 2014-11-05 昂考梅德药品有限公司 Notch1结合剂及其使用方法
US20130095493A1 (en) * 2011-10-03 2013-04-18 The Johns Hopkins University Identification of the gene notch3 as a novel biomarker for human metastatic melanoma
TW201329105A (zh) 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
US20150140043A1 (en) * 2012-05-10 2015-05-21 Institut National De La Sante De La Recherche Medical (Inserm) Immunomodulatory methods using notch agonists
MX2015005810A (es) * 2012-11-07 2015-09-23 Pfizer Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
DK2935330T3 (da) * 2012-12-19 2019-07-22 Aveo Pharmaceuticals Inc Anti-notch3-antistoffer
EP2970479B1 (en) * 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
US9683039B2 (en) * 2013-03-14 2017-06-20 New York University Notch agonists for the treatment of cancer
BR112016028537A2 (pt) * 2014-06-04 2017-08-22 Hutchinson Fred Cancer Res expansão e enxerto de células-tronco utilizando agonistas de notch 1 e/ou de notch 2
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
WO2016046053A1 (en) * 2014-09-25 2016-03-31 H. Lundbeck A/S Immunological treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
CN109715206B (zh) 2016-03-31 2023-11-07 恩格姆生物制药公司 结合蛋白及其使用方法
ES2931955T3 (es) * 2016-04-29 2023-01-05 Aveo Pharmaceuticals Inc Anticuerpo anti-Notch3
WO2018183213A1 (en) 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Blood biomarkers and diagnostic methods for small vessel diseases
US11453718B2 (en) 2017-03-27 2022-09-27 The Schepens Eye Research Institute, Inc. NOTCH3 agonist compositions and methods for treating small vessel diseases
CA3074126A1 (en) * 2017-08-29 2019-03-07 Veritas Therapeutics Inc. Fgl2 antibodies and binding fragments thereof and uses thereof
CA3110089A1 (en) 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
JP6892180B2 (ja) * 2018-12-03 2021-06-23 株式会社ｍＡｂＰｒｏｔｅｉｎ 活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
CN115943163A (zh) * 2020-06-30 2023-04-07 中外制药株式会社 位点特异性Notch激活分子及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20050158859A1 (en) 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US6692919B1 (en) * 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6436650B1 (en) 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
FR2777285B1 (fr) 1998-04-10 2000-05-19 Bio Merieux Ligand peptidique presentant une affinite specifique vis-a-vis de la proteine p24 du retrovirus hiv-1
JP2002526109A (ja) 1998-10-02 2002-08-20 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ アポトーシス誘導物質と方法
US8084258B2 (en) 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
AU2001288628A1 (en) * 2000-08-31 2002-03-13 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
JP4365583B2 (ja) 2000-09-22 2009-11-18 ジェネンテック・インコーポレーテッド ノッチレセプターアゴニスト及び用途
JP2006513260A (ja) 2002-08-03 2006-04-20 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路調節因子の複合体およびその薬物治療への使用
US7837993B2 (en) * 2004-03-19 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for regeneration of aged skeletal muscle tissues
WO2006017173A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
WO2006068822A1 (en) 2004-12-20 2006-06-29 Genentech, Inc. Notch receptor agonists and uses
EP1962895B2 (en) * 2005-12-16 2016-01-20 Regeneron Pharmaceuticals, Inc. THERAPEUTIC USE OF A Dll4 ANTAGONIST AND A VEGF INHIBITOR FOR INHIBITING TUMOR GROWTH
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
CL2007002989A1 (es) 2006-10-19 2008-05-16 Genentech Inc Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3.
CA2666672A1 (en) 2006-10-19 2008-05-02 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
AU2007333805B2 (en) * 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica

Also Published As

Publication number Publication date
AR063494A1 (es) 2009-01-28
US8187839B2 (en) 2012-05-29
MA30900B1 (fr) 2009-11-02
EP2087006B1 (en) 2016-06-08
AU2007309229B8 (en) 2013-05-09
BRPI0715989A8 (pt) 2018-03-13
US20100111971A9 (en) 2010-05-06
CR10730A (es) 2009-06-19
PH12015500576A1 (en) 2016-07-25
KR20150023953A (ko) 2015-03-05
US20110206675A1 (en) 2011-08-25
JP5478254B2 (ja) 2014-04-23
AU2007309229A2 (en) 2009-05-28
WO2008051797A3 (en) 2008-07-31
US20140093889A1 (en) 2014-04-03
WO2008051797A2 (en) 2008-05-02
US20080131908A1 (en) 2008-06-05
EP2087006A2 (en) 2009-08-12
JP2010506596A (ja) 2010-03-04
AU2007309229A1 (en) 2008-05-02
US7915390B2 (en) 2011-03-29
BRPI0715989A2 (pt) 2014-03-18
KR101525629B1 (ko) 2015-06-26
NO20091926L (no) 2009-07-17
CO6180445A2 (es) 2010-07-19
US20080118520A1 (en) 2008-05-22
US9518124B2 (en) 2016-12-13
RU2461569C2 (ru) 2012-09-20
AU2007309229B2 (en) 2013-01-10
CA2666672A1 (en) 2008-05-02
KR20090080979A (ko) 2009-07-27
US20120213785A1 (en) 2012-08-23
TW200824707A (en) 2008-06-16
CL2007002987A1 (es) 2008-06-06
RU2009118621A (ru) 2010-11-27
MX2009004106A (es) 2009-04-28
US7994285B2 (en) 2011-08-09

Similar Documents

Publication Publication Date Title
PE20081264A1 (es) Anticuerpos agonistas anti-notch3
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
ES2689080T3 (es) Anticuerpos que se unen a TL1A y sus usos
CO6230996A2 (es) Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
UY29283A1 (es) Anticuerpos ab(beta)usados en mejorar la cognicion
EA201791127A1 (ru) Антитела, содержащие модифицированные константные участки тяжелой цепи
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
PE20071055A1 (es) Anticuerpos anti mn
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
MX384227B (es) Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis.
PE20140196A1 (es) Anticuerpos anti-cd37
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201170157A1 (ru) Notch-связывающие агенты и антагонисты и способы их применения
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed